Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24


Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review.

Berlie H, Hurren KM, Pinelli NR.

Diabetes Metab Syndr Obes. 2012;5:165-74. doi: 10.2147/DMSO.S27528.


Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.

Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E.

Exp Diabetes Res. 2012;2012:672658. doi: 10.1155/2012/672658.


Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.

Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, Zdravkovic M, Chapman IM.

Diabetes Res Clin Pract. 2012 Aug;97(2):258-66. doi: 10.1016/j.diabres.2012.02.016.


Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.

Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita K, Imagawa A, Funahashi T, Shimomura I.

Cardiovasc Diabetol. 2011 Dec 1;10:109. doi: 10.1186/1475-2840-10-109.


Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins.

Ansar S, Koska J, Reaven PD.

Cardiovasc Diabetol. 2011 Jul 7;10:61. doi: 10.1186/1475-2840-10-61. Review.


Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes.

Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO, Brancati FL, Peters A, Wagenknecht L; Look AHEAD Research Group..

Diabetes Care. 2011 Jul;34(7):1481-6. doi: 10.2337/dc10-2415.


Association between body-mass index and risk of death in more than 1 million Asians.

Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, He J, Gupta PC, Ramadas K, Tsugane S, Irie F, Tamakoshi A, Gao YT, Wang R, Shu XO, Tsuji I, Kuriyama S, Tanaka H, Satoh H, Chen CJ, Yuan JM, Yoo KY, Ahsan H, Pan WH, Gu D, Pednekar MS, Sauvaget C, Sasazuki S, Sairenchi T, Yang G, Xiang YB, Nagai M, Suzuki T, Nishino Y, You SL, Koh WP, Park SK, Chen Y, Shen CY, Thornquist M, Feng Z, Kang D, Boffetta P, Potter JD.

N Engl J Med. 2011 Feb 24;364(8):719-29. doi: 10.1056/NEJMoa1010679.


Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies.

Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M.

Am J Med. 2011 Jan;124(1 Suppl):S35-53. doi: 10.1016/j.amjmed.2010.11.004. Review.


Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice.

Kawashima S, Matsuoka TA, Kaneto H, Tochino Y, Kato K, Yamamoto K, Yamamoto T, Matsuhisa M, Shimomura I.

Biochem Biophys Res Commun. 2011 Jan 7;404(1):534-40. doi: 10.1016/j.bbrc.2010.12.021.


Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease.

Yamaoka-Tojo M, Tojo T, Takahira N, Matsunaga A, Aoyama N, Masuda T, Izumi T.

Cardiovasc Diabetol. 2010 May 14;9:17. doi: 10.1186/1475-2840-9-17.


Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.

Seino Y, Rasmussen MF, Nishida T, Kaku K.

Curr Med Res Opin. 2010 May;26(5):1013-22. doi: 10.1185/03007991003672551.


The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies.

Blonde L, Russell-Jones D.

Diabetes Obes Metab. 2009 Dec;11 Suppl 3:26-34. doi: 10.1111/j.1463-1326.2009.01075.x. Review.


Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.

Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME; NN8022-1807 Study Group..

Lancet. 2009 Nov 7;374(9701):1606-16. doi: 10.1016/S0140-6736(09)61375-1. Erratum in: Lancet. 2010 Mar 20;375(9719):984.


Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.

Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group..

Diabetologia. 2009 Oct;52(10):2046-55. doi: 10.1007/s00125-009-1472-y.


Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides.

Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D.

J Clin Endocrinol Metab. 2009 Jun;94(6):1843-52. doi: 10.1210/jc.2008-1296. Review.


Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

Højberg PV, Vilsbøll T, Rabøl R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S.

Diabetologia. 2009 Feb;52(2):199-207. doi: 10.1007/s00125-008-1195-5.


Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.

Seino Y, Rasmussen MF, Zdravkovic M, Kaku K.

Diabetes Res Clin Pract. 2008 Aug;81(2):161-8. doi: 10.1016/j.diabres.2008.03.018.


Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes.

Højberg PV, Zander M, Vilsbøll T, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S.

Diabetologia. 2008 Apr;51(4):632-40. doi: 10.1007/s00125-008-0943-x.


Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG.

Curr Med Res Opin. 2008 Jan;24(1):275-86.

Items per page

Supplemental Content

Support Center